JoannaMeehanRhodesMDMSCE

Oncology • New Hyde Park, NY

Physician

Join to view full profile

Dr. Rhodes is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rhodes' full profile

Already have an account?

Office
410 Lakeville Rd
Ste 212
New Hyde Park, NY 11042
Phone+1 516-470-4050

Education & Training

University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2016 - 2019
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2013 - 2016
Stony Brook University Health Sciences Center School of MedicineClass of 2013

Certifications & Licensure

NY State Medical License 2019 - 2026
NJ State Medical License 2023 - 2025
PA State Medical License 2016 - 2019
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Real-World Treatment Patterns After Discontinuation of Venetoclax or BTKis in the Frontline Setting Among Older Adults With Chronic Lymphocytic Leukemia.
Scott F Huntington, Joanna M Rhodes, Beenish S Manzoor, Dureshahwar Jawaid, Justin T Puckett
JCO Oncology Practice. 2024-12-20
Treatment Effectiveness of Venetoclax-Based Therapy After Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: An International Real-World Study.
Nilanjan Ghosh, Toby A Eyre, Jennifer R Brown, Nicole Lamanna, Beenish S Manzoor
American Journal of Hematology. 2024-12-19
3 citations
Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from t...
William G Wierda, Nirav N Shah, Chan Y Cheah, David Lewis, Marc S Hoffmann
The Lancet. Haematology. 2024-09-01

Abstracts/Posters

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement
Joanna M Rhodes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Joanna Rhodes, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Outcomes of Patients with Refractory Peripheral T-Cell Lymphoma, Angioimmunoblastic and Other Nodal Lymphomas of T Follicular Helper-Cell Origin (OPerA)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

Vitamin D Boosts Treatment-Free Survival in Some CLL Patients, Study ShowsAugust 13th, 2024
Rhodes Assesses Toxicity Concerns for ABVD and Brentuximab Vedotin in cHLJune 29th, 2024
Oncternal Therapeutics : Lee 2022 ASCO Poster Zilovertamab + Ibrutinib for MCL and CLLJune 7th, 2022
Join now to see all